Renal cell cancer and sorafenib: Skin toxicity and treatment outcome

Emilio Bajetta, Giuseppe Procopio, Elena Verzoni, Laura Catena, Sara De Dosso, Marco Platania, Arpine Gevorgyan

Research output: Contribution to journalArticle


We describe the case of a young man with refractory renal cell carcinoma who achieved an objective response in a metastatic lesion after biotherapy with the multikinase inhibitor sorafenib and also developed a severe skin reaction. The patient had been previously treated with various combinations of immunochemotherapy without any clinical benefit. We performed a brief review of the literature where similar cases were documented with the use of various anti-EGFR agents. The hypothesis of the correlation of skin toxicity with disease response is not new, but in the absence of any strong evidence remains controversial.

Original languageEnglish
Pages (from-to)201-203
Number of pages3
Issue number2
Publication statusPublished - Mar 2007



  • Multikinase inhibitor
  • Rash
  • Renal cancer
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research

Cite this

Bajetta, E., Procopio, G., Verzoni, E., Catena, L., De Dosso, S., Platania, M., & Gevorgyan, A. (2007). Renal cell cancer and sorafenib: Skin toxicity and treatment outcome. Tumori, 93(2), 201-203.